FDA Grants Approval for Rifapentine ANDA217042 by Macleods Pharmaceuticals
The FDA has granted approval for the ANDA217042 application for Rifapentine submitted by Macleods Pharmaceuticals.
Asset / Drug
Drug and asset intelligence for Rifapentine with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.